Driving Research Breakthroughs

Susan G. Komen® is leading the way in the fight against breast cancer, driving innovation and funding more breast cancer research than any other nonprofit.*

As part of our comprehensive, 360-degree approach to fighting this disease across all fronts, we are funding lifesaving research, advocating for compassionate public policy, offering financial assistance for patients, providing trustworthy breast cancer information, and ensuring patient support every step of the way.

Today, we are leveraging our leadership position to focus increased research attention on metastatic breast cancer, eliminating disparities in outcomes, and advancing the use of technology to improve patient care and save lives.

We are funding innovative studies to develop new ways to treat, detect, prevent and ultimately cure all forms of breast cancer. This work is guided by patient advocates and the world’s leaders in breast cancer research. Here is a snapshot of how Susan G. Komen is advancing research.

ON ANY GIVEN DAY:

More than 150 Komen-funded research teams across five countries are working to end breast cancer.

Close to 90 Komen-funded research labs are studying metastatic breast cancer.

There have been nearly 13,000 donations to the Komen Tissue Bank by women who are helping scientists transform breast cancer research.

79 new breast cancer treatments are being discovered and tested—31 of these for triple negative breast cancer, which needs better treatment options.

More than 30 Komen-funded projects are identifying and testing new approaches to reduce breast cancer disparities.

More than 200 patient advocates are working to ensure the patient perspective is included in ongoing Komen-funded research and Komen-funded research programs.

53 world-leading scientists and advocates are guiding and prioritizing Komen’s research investment.

81 new biomarkers are being discovered and tested to help diagnose people and tailor personal treatment strategies.

*Funding since 1987 as compared to all nonprofits outside the U.S. government